-
公开(公告)号：US11759515B2
公开(公告)日：2023-09-19
申请号：US17196890
申请日：2021-03-09
Applicant: Arcturus Therapeutics, Inc.
Inventor： Sean Michael Sullivan , Daiki Matsuda , Kiyoshi Tachikawa , Padmanabh Chivukula , Priya Prakash Karmali , Jared Henry Davis , Yanjie Bao
IPC: A61K39/215 , C07K14/005 , C12N15/86 , A61K47/20 , A61K47/26 , A61K47/10 , A61K9/51 , A61K39/12 , C07K14/18 , C12N7/00 , A61K39/00 , A61K38/00
CPC classification number: A61K39/215 , A61K9/5123 , A61K39/12 , A61K47/10 , A61K47/20 , A61K47/26 , C07K14/005 , C07K14/1808 , C12N7/00 , C12N15/86 , A61K38/00 , A61K2039/53 , C12N2770/20022 , C12N2770/20034 , C12N2770/36122 , C12N2770/36134 , C12N2830/42 , C12N2830/50
Abstract: Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.
-
公开(公告)号：US11744887B2
公开(公告)日：2023-09-05
申请号：US17196889
申请日：2021-03-09
Applicant: Arcturus Therapeutics, Inc.
Inventor： Sean Michael Sullivan , Daiki Matsuda , Kiyoshi Tachikawa , Padmanabh Chivukula , Priya Prakash Karmali , Jared Henry Davis , Yanjie Bao , Amit Sagi
IPC: A61K39/215 , C07K14/005 , C12N15/86 , A61K47/20 , A61K47/26 , A61K47/10 , A61K9/51 , A61K39/12 , C07K14/18 , C12N7/00 , A61K39/00 , A61K38/00
CPC classification number: A61K39/215 , A61K9/5123 , A61K39/12 , A61K47/10 , A61K47/20 , A61K47/26 , C07K14/005 , C07K14/1808 , C12N7/00 , C12N15/86 , A61K38/00 , A61K2039/53 , C12N2770/20022 , C12N2770/20034 , C12N2770/36122 , C12N2770/36134 , C12N2830/42 , C12N2830/50
Abstract: Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.
-
公开(公告)号：US11685906B2
公开(公告)日：2023-06-27
申请号：US16705102
申请日：2019-12-05
Applicant: Arcturus Therapeutics, Inc.
Inventor： Carlos G. Perez-Garcia , Kiyoshi Tachikawa , Daiki Matsuda , Padmanabh Chivukula
CPC classification number: C12N9/1018 , A61P9/00 , C12Y201/03003 , A61K48/00
Abstract: The present disclosure provides a modified human OTC protein having improved properties for the treatment of OTC deficiency in a patient. Preferably, the protein of the disclosure is produced from a codon optimized mRNA suitable for administration to a patient suffering from OTC deficiency wherein upon administration of the mRNA to the patient, the protein of the disclosure is expressed in the patient in therapeutically effective amounts to treat OTC deficiency. The present disclosure also provides codon optimized mRNA sequences encoding wild type human OTC comprising a 5′ UTR derived from a gene expressed by Arabidopsis thaliana for use in treating OTC deficiency in a patient.
-
公开(公告)号：US12220455B2
公开(公告)日：2025-02-11
申请号：US18345893
申请日：2023-06-30
Applicant: Arcturus Therapeutics, Inc.
Inventor： Sean Michael Sullivan , Daiki Matsuda , Kiyoshi Tachikawa , Padmanabh Chivukula , Priya Prakash Karmali , Jared Henry Davis , Yanjie Bao , Amit Sagi
IPC: A61K39/215 , A61K9/51 , A61K38/00 , A61K39/00 , A61K39/12 , A61K47/10 , A61K47/20 , A61K47/26 , C07K14/005 , C07K14/18 , C12N7/00 , C12N15/86
Abstract: Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.
-
Patent Agency Ranking
公开(公告)号：US12070509B2
公开(公告)日：2024-08-27
申请号：US17246558
申请日：2021-04-30
Applicant: Arcturus Therapeutics, Inc.
Inventor： Carlos G. Perez-Garcia , Kiyoshi Tachikawa , Daiki Matsuda , Padmanabh Chivukula , Priya Prakash Karmali , Yanjie Bao , Jerel Boyd Lee Vega , Rajesh Mukthavaram , Amit Sagi
CPC classification number: A61K48/0033 , A61K48/005 , A61P11/00 , C07K14/4702
Abstract: Nucleotides encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein are provided herein. Also describe are mRNA constructs that can be used to express CFTR protein in vitro or in vivo. The mRNA constructs can be formulated in a lipid formulation and administered via inhalation to treat cystic fibrosis.
-
公开(公告)号：US11939363B2
公开(公告)日：2024-03-26
申请号：US17812576
申请日：2022-07-14
Applicant: ARCTURUS THERAPEUTICS, INC.
Inventor： Pattraranee Limphong , Kiyoshi Tachikawa , Padmanabh Chivukula , Daiki Matsuda , Arisa Cale
IPC: C07K14/505 , A61K31/7115 , A61K38/17 , A61K38/18 , A61K38/48 , C07K14/575 , C07K14/745 , C07K14/81 , A61K38/00 , C12Q1/68
CPC classification number: C07K14/505 , A61K31/7115 , A61K38/1709 , A61K38/1816 , A61K38/482 , A61K38/4846 , C07K14/575 , C07K14/745 , C07K14/81 , A61K38/00
Abstract: A range of therapeutic mRNA molecules expressible to provide a target polypeptide or protein. The RNA molecules can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided are DNA templates, which can be transcribed to provide a target mRNA, and can have altered nucleotides, such as reduced deoxyadenosines. Also provided are processes for making the therapeutic mRNA molecules. The RNA molecules can be translated in vitro or in vivo to provide an active polypeptide or protein. The RNA molecules can be included in a composition used for preventing, treating, or ameliorating at least one symptom of a disease or condition in a subject in need thereof.
-
公开(公告)号：US11407800B2
公开(公告)日：2022-08-09
申请号：US15907123
申请日：2018-02-27
Applicant: Arcturus Therapeutics, Inc.
Inventor： Pattraranee Limphong , Kiyoshi Tachikawa , Padmanabh Chivukula , Daiki Matsuda , Arisa Cale
IPC: C12N15/10 , C07K14/505 , C07K14/745 , C07K14/575 , C07K14/81 , A61K38/48 , A61K38/17 , A61K38/18 , A61K31/7115 , A61K38/00
Abstract: A range of therapeutic mRNA molecules expressible to provide a target polypeptide or protein. The RNA molecules can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided are DNA templates, which can be transcribed to provide a target mRNA, and can have altered nucleotides, such as reduced deoxyadenosines. Also provided are processes for making the therapeutic mRNA molecules. The RNA molecules can be translated in vitro or in vivo to provide an active polypeptide or protein. The RNA molecules can be included in a composition used for preventing, treating, or ameliorating at least one symptom of a disease or condition in a subject in need thereof.
-
公开(公告)号：US20220023442A1
公开(公告)日：2022-01-27
申请号：US17246558
申请日：2021-04-30
Applicant: Arcturus Therapeutics, Inc.
Inventor： Carlos G. Perez-Garcia , Kiyoshi Tachikawa , Daiki Matsuda , Padmanabh Chivukula , Priya Prakash Karmali , Yanjie Bao , Jerel Boyd Lee Vega , Rajesh Mukthavaram , Amit Sagi
Abstract: Nucleotides encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein are provided herein. Also describe are mRNA constructs that can be used to express CFTR protein in vitro or in vivo. The mRNA constructs can be formulated in a lipid formulation and administered via inhalation to treat cystic fibrosis.
-
公开(公告)号：US20180327471A1
公开(公告)日：2018-11-15
申请号：US15907123
申请日：2018-02-27
Applicant: Arcturus Therapeutics, Inc.
Inventor： Pattraranee Limphong , Kiyoshi Tachikawa , Padmanabh Chivukula , Daiki Matsuda , Arisa Cale
IPC: C07K14/505 , C07K14/745 , C07K14/81 , C07K14/575
CPC classification number: C07K14/505 , A61K31/7088 , A61K31/7105 , A61K35/545 , A61K38/00 , A61K38/17 , C07K14/575 , C07K14/745 , C07K14/81
Abstract: A range of therapeutic mRNA molecules expressible to provide a target polypeptide or protein. The RNA molecules can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided are DNA templates, which can be transcribed to provide a target mRNA, and can have altered nucleotides, such as reduced deoxyadenosines. This invention also provides processes for making the therapeutic mRNA molecules. The RNA molecules can be translated in vitro or in vivo to provide an active polypeptide or protein.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.023 seconds)
